TIMCC
Tumor Infiltrating Myeloid Cell Compartment
| Coordinatore | ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 3˙756˙469 € |
| EC contributo | 3˙756˙469 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2012-ITN |
| Funding Scheme | MC-ITN |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-11-01 - 2016-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | coordinator | 870˙434.20 |
| 2 |
QUEEN MARY UNIVERSITY OF LONDON
Organization address
address: 327 MILE END ROAD contact info |
UK (LONDON) | participant | 573˙413.25 |
| 3 |
UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
SE (UPPSALA) | participant | 523˙150.30 |
| 4 |
STICHTING HET NEDERLANDS KANKER INSTITUUT
Organization address
address: PLESMANLAAN 121 contact info |
NL (AMSTERDAM) | participant | 477˙022.90 |
| 5 |
RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN
Organization address
address: REGINA PACIS WEG 3 contact info |
DE (BONN) | participant | 447˙437.75 |
| 6 |
TECHNISCHE UNIVERSITAET DRESDEN
Organization address
address: HELMHOLTZSTRASSE 10 contact info |
DE (DRESDEN) | participant | 447˙437.75 |
| 7 |
ALLIGATOR BIOSCIENCE AB
Organization address
address: SCHEELEVAGEN 19A contact info |
SE (LUND) | participant | 226˙772.05 |
| 8 |
SYNOVO GMBH
Organization address
address: Paul Ehrlich Str 15 contact info |
DE (TUEBINGEN) | participant | 190˙800.72 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The ITN TIMCC brings together eight expert teams from different disciplines within Immunology, Genetics and Oncology, to provide substantive and methodological training in the analysis of the role of the Tumor Infiltrating Myeloid Cell Compartment (TIMCC) of the innate immune system. Leukocytes recruited to (pre)malignant tissues are mainly myeloid cells. They can either prevent or functionally contribute to cancer development. However, the mechanisms underlying pro- versus anti-tumor programming of neoplastic tissues by these immune cells remain obscure. The ITN TIMCC aims to improve anti-tumor therapy by defining general and tumor type specific molecular and cellular immunological pathways (e.g signal transduction and downstream effector pathways) in tumor development and during therapeutic intervention based on an extensive analysis of the infiltrating myeloid cell compartment in human tumor biopsies using a large variety of techniques and functional analysis of the corresponding models of a variety of human tumors, affecting different organs, in a unique cohort of genetically modified mice treated with different types of anti-tumor therapy. The program will train the appointed researchers in a variety of methodology and technology from genomic technologies and bioinformatics via genetically modified mice to the design and application of therapeutic strategies to understand and manipulate the many interactions of the myeloid cell compartment with developing tumors. By defining underlying molecular and cellular pathways new targets will be identified to be explored by the participating SMEs. The program will deliver young researchers equipped with a broad knowledge in immunology, genetics and oncology and insight in the complexity of translational medicine therefore better prepared to meet new challenges in the field.'